research

Nanobiotix S.A. (NBTX) Q4 2025 Earnings Call Transcript

Seeking Alpha

2 min read

0 likes

⚡ Quantum Brief

Nanobiotix reported its Q4 2025 earnings on April 1, 2026, highlighting progress in its clinical pipeline and financial stability. CEO Laurent Levy emphasized key milestones in oncology programs. The company advanced its lead candidate, NBTXR3, with Phase 3 trials for soft tissue sarcoma nearing completion. Regulatory submissions are expected in 2026, targeting potential FDA approval. Financial results showed a €120M cash runway, sufficient to fund operations through 2027. CFO Bart Van Rhijn noted cost discipline amid R&D expansion. Analysts questioned commercialization strategies, particularly in the U.S. and EU. Management reiterated plans for partnerships to accelerate market access. Forward-looking statements warned of risks tied to clinical outcomes, regulatory hurdles, and funding. The call underscored confidence in Nanobiotix’s long-term growth trajectory.

AI Audio Summary

0:00 / 0:00

Click to play

Quantum News · Media Library

Understand this faster with AI

Ask ChatGPT

Research with Perplexity

Explain with Claude

Discuss on Grok

SA Transcripts159.18K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Nanobiotix S.A. (NBTX) Q4 2025 Earnings Call April 1, 2026 8:00 AM EDT Company Participants Joanne ChoiLaurent Levy - Co-Founder, President of the Executive Board & CEOBart Van Rhijn - Chief Financial & Business Officer and Member of Executive Board Conference Call Participants Tara Bancroft - TD Cowen, Research DivisionClemence Thiers - Stifel, Nicolaus & Company, Incorporated, Research DivisionAlbert Agustinus - Leerink Partners LLC, Research DivisionSwayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research DivisionXiaochuan Dai - UBS Investment Bank, Research DivisionMichael Schmidt - Guggenheim Securities, LLC, Research DivisionShan Hama - Jefferies LLC, Research DivisionClément Bassat - Portzamparc BNP Paribas Group, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Nanobiotix Full Year 2025 Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Joanne Choi, Head of Investor Relations, U.S. Please go ahead.

Joanne Choi Thank you, Heidi. Good afternoon, and good morning, and welcome to the Nanobiotix conference call to discuss our full year 2025 financial and operational results. Joining me on the call today are Laurent Levy, Co-Founder and Chief Executive Officer; and Bart Van Rhijn, Chief Financial and Business Officer. Today's call is being webcast and will be available on our website for replay. Before we begin, I would like to remind you that today's discussion will include forward-looking statements within the meaning of applicable securities laws. These statements are based on our current expectations, assumptions and available information and are subject to significant risks and uncertainties that could cause actual results to differ materially. Such risks include, among others, those related to the timing, progress and outcomes of our research and clinical development programs, regulatory developments and our financial and operational performance. We

Read Original

Source Information

Source: Seeking Alpha

Website: https://seekingalpha.com/feed.xml

Discussion

0 professional contributions

Be the first to add a constructive contribution.